Lyka Labs Limited

Corporate Office: Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036.

• Phone: 6511 2200 • Fax: 6611 2249 Website: www.lykalabs.com • Email: enquiry@lykalabs.com

LYKA Healthearre though to mark to

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

	Particulars	Quarter Ended			6 months period ended		Previous Year Ended
		30-Sep-2018	30-Jun-2018	30-Sep-2017	30-Sep-2018	30-Sep-2017	31-Mar-2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue					***	
	Revenue from Operations	613.56	1,135.46	832.00	1,749.02	1,483.09	4,168.09
	Oher Income	30.78	29.36	69.49	60.14	98.07	189.21
n.	Tital Income	644.34	1,164.82	901.49	1,809.16	1,581.16	4,357.30
III.	Expenses			- 1			
) Cist of Materials Consumed	238.11	360.81	452.4	598.93	735.34	1.040.00
	Pirchase of Stock in trade	15.29	304.09	9.66	319.38	84.90	1,848.03 134.25
(0	Clange in inventories of finished goods,	2.55	4.97	12.47	7.53	10.51	134.25
,-	wirk-in-progress and stock-in-trade.	2.55	4.57	12.47	7.55	10.51	1/1.25
(d	Enployee benefits expense	243.97	281.23	321.23	525.20	542.15	1,089.96
) Filance Costs	120.55	105.84	422.09	226.39	845.29	613.47
(f	Depreciation and amortisation expense	155.82	155.05	157.59	310.87	296.90	630.89
) Other expenses	191.11	198.90	440.3	390.01	740.31	1,138.77
	Total Expenses	967.40	1,410.89	1,815.74	2,378.31	3,255.40	5,626.62
IV.	(Lcss)/Profit before Exceptional Items and Taxes (II - III)	(323.06)	(246.07)	(914.25)	(569.15)	(1674.24)	(1269.32)
v.	Exceptional Items (Net)						(147.12)
VI.	(Loss)/Profit before Tax	(323.06)	(246.07)	(914.25)	(569.15)	(1674.24)	(1122.20)
VII.	TaxExpenses (Deferred Tax)	(2.86)	(16.92)	(24.25)	(19.79)	(31.83)	(38.26)
VIII.	Net (Loss)/Profit after Tax	(320.20)	(229.15)	(890.00)	(549.36)	(1642.41)	(1083.94)
IX.	Other Comprehensive Loss / (Income)	7.43	7.43	1.39	14.86	2.78	29.71
X.	Total Comprehensive (Loss) / Income	(327.63)	(236.58)	(891.39)	(564.22)	(1645.19)	(1113.65)
XI.	Paid up Equity Share Capital	2814.00	2814.00	2814.00	2,814.00	2,814.00	2,814.00
	(Face value Rs.10/- each)						
XII.	Other Equity						6,864.14
XIII.	Earnings Per Equity Share						
	of Rs 10/-each (not annualised)	Wisconsti		2000			
	(a) Basic (Rs.)	(1.15)	(0.82)	(3.79)	(1.97)	(6.99)	(4.24)
	(b) Diluted (Rs.)	(1.15)	(0.82)	(3.79)	(1.97)	(6.99)	(4.24)



Lyka Labs Limited

Corporate Office: Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036.

• Phone: 6611 2200 • Fax: 6611 2249 Website: www.lykalabs.com • Email: enquiry@lykalabs.com



Statement of Assets & Liabilities

(Rs.in Lakhs)

		(Rs.in Lakl
Particulars	As at 30th September, 2018	As at 31st March 2018
ASSETS		
1 Non-Current Assets		
(a) Property, Plant and Equipment	7,457.84	7,678.
(b) Capital Work- In- Progress	1,660.18	1,666.
(c) Intangible assets	365.23	438.
(d) Intangible assets under development	1,106.02	976.
	10,589.27	10,759.
(e) Financial Assets		
(i)Investments	6,245.30	6,245.
(ii) Other Financial Assets	1,583.23	1,510.
(f) Other Non Current Assets	152.55	193.
(g) Non Current Tax Assets	392.74	380.
(h) Deferred tax assets(net)	160.63	140.
	8,534.45	8,470.0
Current Assets		
(a) Inventories	743.62	729.9
(b) Financial Assets		
(i)Investments	0.06	0.0
(ii) Trade Receivables	2,670.12	3,014.3
(iii) Cash and Cash Equivalents	70.33	52.7
(iv) Loans	657.33	654.4
(v) Other Financial Assets	154.57	205.1
(c) Other Current Assets	726.03	645.7
	5,022.06	5,302.0
Total Assets	24,145.78	24,531.7
EQUITY AND LIABILITIES		
Equity		
(a) I Equity Share capital	2,814.00	2,814.0
(b) Other Equity	6,300.00	6,864.1
	9,114.00	9,678.1
LIABILITIES		
Non-Current Liabilities		
(a) ! Financial Liabilities		
(i) Borrowings	7,922.06	471.3
(ii) Other Financial Liabilities	25.89	31.8
(b) Provisions	406.76	254.1
	8,354.71	757.3
Current Liabilities		
(a) S Financial Liabilities		
(i) Borrowings	1,016.95	3,558.6
(ii) Trade Payable	2,534.05	2,183.9
(iii) Other Financial Liabilities	2,697.03	8,023.0
(b) Other Current Liabilities	371.71	168.1
(c) Provisions	57.32	162.4
	6,677.07	14,096.2
Total Equity and Liabilities	24,145.78	24,531.7

FOR LYKA LABS LIMITED

Atit Shukla (DIN No. 07238247) (Chairman of the Meeting)



Notes:

- 1. The above unaudited financial results as reviewed by the Audit Committee, have been approved and taken on record at the meeting of the Board of Directors held on 1st Nove Inber, 2018.
- **2.** The Limited Review as required as per listing agreement has been carried out by the Statutory Auditors of the Company.
- 3. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized practices and policies to the extent applicable.
- **4.** The Company has opted to publish only unaudited standalone financial results. The company would be consolidating and presenting its Consolidated Financial Statements as at and for the year ended 31st March, 2019.

5. Inventories:

Inventories include slow/non-moving raw material and packing materials procured during the earlier years amounting to 172.03 lakhs as on 30th September 2018, which are valued at lower than cost. The Company is evaluating to utilize/realise the same.

6. Compromise Settlement:

(a) <u>Compromise Settlement through One Time Settlement (OTS) of debts of Dena Bank</u> <u>and Assignment of debts in favour of International Asset Reconstruction Company</u> <u>Pvt Ltd (IARC)</u>

During the quarter, Dena Bank has entered into compromise settlement with the Company, whereby they have accepted OTS of Rs.5200 lakhs towards full and final settlement of its total dues through the funds arranged from IARC. In turn, they have assigned its total debts in favour of IARC, acting in its capacity as Trustee of IARF- III Trust Scheme vide Deed of Assignment dated 4th September, 2018. Accordingly, all underlying securities and security rights pertaining to the debts also stand assigned in favour of IARC.

On assignment of debts, Dena Bank has issued its No Dues Certificate on 17th September, 2018.

The Company is in the process of formalising the terms of repayment of debts to IARC.

The Company has not accounted for the effect of OTS as well as the treatment of assigned debts in favour of IARC, pending the terms of repayment of debts to IARC.

The effect of the settlement and assignment of debts would be accounted when the final terms are formalised with IARC.



(b) Debts of Bank of Maharashtra

During the quarter, Bank of Maharashtra (BoM), has accorded its approval for full and final settlement of its debts at an amount of Rs.1100 lakhs. The Company has also received in principle confirmation from International Asset Reconstruction Company Pvt

Am.



Ltd (IARC), to acquire entire debts of Bank of Maharashtra (BoM) through assignm ent of debts agreement with BoM by paying off the agreed amount as per full and final settlement. The Company has accepted the compromise proposal subject to certain conditions and is in the process of finalising the terms of compromise settlement with BoM and IARC.

Accordingly, the Company has ceased provision of interest. As per the approval of BoM, if the Company delays payment of the settled amount of debt, BoM shall charge in terest for the delayed period at one-year MCLR rate from 1st December, 2018.

7. Pledged shares of a Director encashed by a Lender:

Bank of Maharashtra has invoked 160,000 equity shares of the Company pledged by the CEO of the Company. Out of the invoked equity shares, 110,000 equity shares were sold by the Bank and the sales proceeds aggregating to Rs. 51.46 lakhs adjusted against the outstanding Term Loan.

This amount of Rs.51.46 lakhs has been reflected as Unsecured Loan from the CEO.

8. Scheme of Arrangements: -

- (a) The Board of Directors at their meeting held on 10th March, 2016 resolved to merge Company's Subsidiary i.e. Lyka Exports Limited with it, effective from 1st April, 2015 ("Appointed Date") under the provisions of sections 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30th November, 2015. Since then the "appointed date" of the said merger of Lyka Exports Limited is postponed to 1st April, 2017 by the Board of Directors at their meeting held on 30th August, 2017.
- (b) The Board of Directors at their meeting held on 29th May 2017, resolved to merge Company's subsidiary Lyka Healthcare Limited with it effective from 1st April 2017 ("Appointed Date") under the provisions of sections 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30th November, 2015.

The National Company Law Tribunal (NCLT), Ahmedabad approved the application vide its order dated 6th February 2018 and ordered to call Equity/ Preference Shareholders and Secured/ Unsecured Creditors meeting on 27th March 2018 for approving the arrangement

LA LA ON THE PROPERTY OF THE P

The Equity / Preference Shareholders at the meetings convened, approved the arrangements of merger. The Unsecured Creditors at their meeting also approved the arrangement of merger. However, the meeting of Secured Creditors could not be proceeded, due of lack of quorum. Accordingly, the Company filed an interlocutory Application on 13th April 2018, before NCLT seeking directions for re-convening / conducting a fresh meeting of the Secured Creditors. Pursuant to Interlocutory Application, NCLT passed an order dated 9th May, 2018 directing the Company for reconvening meeting of Secured Creditors on 2nd July, 2018.

P

An



Accordingly, Secured Creditors' Meeting was called on 2nd July, 2018 as per NCLT order which stood adjourned due to lack of quorum for further consideration to Monday, 9th July, 2018. Further, the adjourned meeting on 9th July, 2018 could not be proceede d due to lack of quorum. NCLT had convened the meeting on 28th September 2018, but at the request of the Company for adjournment, NCLT has fixed the meeting on 15th Nove Ther, 2018.

9. Capital Expenditure:

The Company reviews its portfolio of products under development and applied research regularly. Accordingly, a sum of Rs. 55.69 lakhs incurred during the quarter is carried forward as "Intangible Assets under development" to be recognized as "Self-Gene rated Intangible Assets" upon successful development and commercial viability of the respective products. However, the carrying cost of those product's which do not confirm to the test of commercial viability are charged to the Statement of Profit and Loss.

- **10.** The format for quarterly results as prescribed in SEBI's Circular CIR/CFB/CMD/15/20**1**5 dt. Nov 30, 2015 has been modified to comply with the requirements of SEBI's circular dt. Jul 5, 2016.
- **11.** Post applicability of Goods and Service Tax (GST) w.e.f. July 1, 2017, the "Revenue from Operations" is disclosed net of GST. However, the "Revenue from operations" for the half year ended 30th September, 2017, are inclusive of excise duty, and is not comparable with "Revenue from operations" for the half year ended 30th September, 2018 to that extent.
- **12.** Ind AS 115, Revenue from Contracts with Customers, mandatory for reporting periods beginning on or after 1st April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1st April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 13. The Company operates in one reportable business segment i.e. "Pharmaceuticals".

14. The figures for previous year /period have been regrouped/rearranged wherever considered necessary.

For LYKA LABS LIMITED

Mumbai 1st November, 2018 ATIT N.SHUKLA(DIN:07238247)
(Chairman of the Meeting)

Mehta Chokshi & Shah CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors, Lyka Labs Limited

- 1. We have reviewed the accompanying statement of standalone 'Un-audited financial results' of Lyka Labs Limited ("the Company") for the quarter ended 30th September, 2018 and the year to date results for the period from 1st April, 2018 to 30th September, 2018 ("the Statement") (which includes the Statement of the Company's branch at Ankleshwar reviewed by other auditor and relied upon by us, after making such changes as are considered necessary for incorporation) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- 2. This Statement which is the responsibility of the Company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our limited review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Basis of Qualification

Inventories

Inventories include slow/non-moving raw material and packing materials procured during the earlier years amounting to 172.03 lakhs as on 30th September, 2018, which are valued at cost. This is not in accordance with Ind AS 2 Inventories, which requires such inventories to be valued at lower of cost or net realizable value. Accordingly, we are unable to quantify the impact of increase in loss for the quarter ended 30th September, 2018.

5. Qualified Opinion

Based on our review conducted and subject to possible effects of the matter described in para 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed

MAKER BHAVAN 3, 214, 2ND FLOOR, NEW MARINE LINES, MUMBAI - 400 020. TEL.: 2205 7309 • 2208 8743 • 6633 4067 • 2205 5432 • Email: mcs@camcs.in



the information required to be disclosed in terms Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to:

A. Compromise Settlement

Note No.6 (a) and (b) regarding compromise settlement with Dena Bank and Bank of Maharashtra by assignment of debts in favour of International Assets Reconstruction Company Pvt Ltd (IARC).

B. Pledged shares of the CEO encashed by a Lender

Note No.7 regarding invoking of the pledged shares of the Company held by the CEO and part encashment of the same by a lender aggregating to Rs 51.46 lakhs.

C. Scheme of Arrangements

Note No.8 (a) & (b) regarding the pending status of merger with Lyka Exports Limited and Lyka Healthcare Limited.

D. Capital Expenditure:

Note No. 9 regarding the review of the portfolio of products under development and applied research.

Our report is not modified in respect of these matters.

7. We did not review the financial results and other financial information of Ankaleshwar Branch ("the Branch), whose financial results shows loss of Rs.50.73 lakhs for the quarter ended 30th September 2018 and loss of Rs 86.61 for the half year ended 30th September 2018. These financial results and other financial information have been reviewed by other auditor, and their review report has been furnished to us by the management. Our opinion, in so far as it relates to the affairs of the Branch is based solely on the report of other auditor.

Our report is not modified in respect of these matters.

JMBAI **

For Mehta Chokshi & Shah. Chartered Accountants Firm Reg. No. 106201W

> Name: Abhay Mehta Membership No. 046088

Place: Mumbai

Date: 1st November, 2018